Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
New Publication from MedNewsWeek. Incredibly proud of this group of trainees who stepped up to co-author this manuscript alongside Dr. Chandler Park. This is what mentorship is supposed to look like – challenge them elevate them give them a platform watch them grow.
At MedNewsWeek, we don’t just talk about developing future leaders in oncology – we actively build them. Seeing trainees move from learners to published authors is exactly why we do this. Grateful to Ariana Pelosci for the opportunity to publish this important work in oncology. We truly appreciate the platform to contribute to meaningful conversations shaping cancer care.
Now – let’s talk about the science. This article dives into the evolving treatment landscape of multiple myeloma and why the conversation is more dynamic than ever: ASCT still matters.
Despite game-changing advances, autologous stem cell transplant remains a foundational strategy in frontline-eligible patients. Landmark trials (DETERMINATION, IFM 2009) reinforce deeper progression-free survival with early transplant – even in the era of modern induction regimens. MRD is reshaping personalization. Minimal residual disease assessment is becoming critical in determining who benefits most and how we tailor therapy. CAR-T and bispecific are redefining relapse.
Cellular therapy and immune redirection strategies are revolutionizing refractory myeloma – and may change sequencing paradigms altogether.
The big question: How do we optimally integrate transplant, cellular therapy, and precision approaches to maximize durability while minimizing toxicity?
That’s where oncology is headed. The future isn’t just novel drugs. It’s strategy. It’s precision. It’s training the next generation to think critically about integration. And we’re all in.”
Title: Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?
Authors: Taha Kassim Dohadwala, Jenna Ghazal, Soumiya Nadar, Riya Vaishnav, Ishan Paduvagere, Viviana Cortiana, Chandler H. Park, Yan Leyfman
Read The Full Article
Other articles featuring Multiple Myeloma on OncoDaily.